The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients.

[1]  Paulette Mehta,et al.  Wintrobe’s Clinical Hematology , 2009 .

[2]  S. Colla,et al.  CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions. , 2008, Cancer research.

[3]  C. Bokemeyer,et al.  The Local Cytokine and Chemokine Milieu within Malignant Effusions , 2008, Tumor Biology.

[4]  M. Kandefer-Szerszeń,et al.  Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells , 2008, Archivum Immunologiae et Therapiae Experimentalis.

[5]  T. Uchiyama,et al.  Growth and differentiation advantages of CD4+ OX40+ T cells from allogeneic hematopoietic stem cell transplantation recipients. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  G. Vogelsang,et al.  Chronic graft versus host disease , 2004, British journal of haematology.

[7]  Ann Richmond,et al.  Role of chemokines in tumor growth. , 2007, Cancer letters.

[8]  B. Han,et al.  Low-Dose Paclitaxel Prior to Intratumoral Dendritic Cell Vaccine Modulates Intratumoral Cytokine Network and Lung Cancer Growth , 2007, Clinical Cancer Research.

[9]  K. Moriyama,et al.  Myeloma Cell-Osteoclast Interaction Enhances Angiogenesis Together with Bone Resorption: A Role for Vascular Endothelial Cell Growth Factor and Osteopontin , 2007, Clinical Cancer Research.

[10]  A. Zlotnik.  Chemokines and cancer , 2006, International journal of cancer.

[11]  G. Roodman,et al.  Chemokines in multiple myeloma. , 2006, Experimental hematology.

[12]  B. Han,et al.  Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? , 2006, Cancer and Metastasis Reviews.

[13]  E. Zorn.  CD4+CD25+ regulatory T cells in human hematopoietic cell transplantation. , 2006, Seminars in cancer biology.

[14]  Andreas Radbruch,et al.  Long-lived plasma cells in immunity and immunopathology. , 2006, Immunology letters.

[15]  S. Colla,et al.  CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. , 2006, Haematologica.

[16]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Ribatti,et al.  Bone marrow endothelial cells in multiple myeloma secrete CXC‐chemokines that mediate interactions with plasma cells , 2005, British journal of haematology.

[18]  R. Kyle,et al.  Drug therapy: Multiple myeloma , 2004 .

[19]  J. Christensen,et al.  A Selective c-Met Inhibitor Blocks an Autocrine Hepatocyte Growth Factor Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma Cells , 2004, Clinical Cancer Research.

[20]  D. Ribatti,et al.  CXCR3-binding chemokines in multiple myeloma. , 2004, Cancer letters.

[21]  N. Callander,et al.  And Growth of Myeloma Cells Il-3 Expression by Myeloma Cells Increases Both Osteoclast Formation , 2022 .

[22]  K. Perisinakis,et al.  Serum level of interleukin‐16 in multiple myeloma patients and its relationship to disease activity , 2004, American journal of hematology.

[23]  M. Ellis,et al.  Insulin-like growth factors in human breast cancer , 2004, Breast Cancer Research and Treatment.

[24]  V. Lauta,et al.  A review of the cytokine network in multiple myeloma , 2003, Cancer.

[25]  R. Bende,et al.  The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma , 2003, Leukemia.

[26]  K. Vanderkerken,et al.  Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3 , 2003, British Journal of Cancer.

[27]  K. Wood,et al.  Regulatory lymphocytes: Regulatory T cells in transplantation tolerance , 2003, Nature Reviews Immunology.

[28]  G. Nilsson,et al.  Expression and function of chemokine receptors in human multiple myeloma , 2003, Leukemia.

[29]  K. Rezvani,et al.  New developments in allotransplant immunology. , 2003, Hematology. American Society of Hematology. Education Program.

[30]  F. Dammacco,et al.  [Chemokines and tumors]. , 2002, Recenti progressi in medicina.

[31]  Andreas Radbruch,et al.  Chemotactic Responsiveness Toward Ligands for CXCR3 and CXCR4 Is Regulated on Plasma Blasts During the Time Course of a Memory Immune Response1 , 2002, The Journal of Immunology.

[32]  A. Janin,et al.  Activated eosinophils in upper gastrointestinal tract of patients with graft-versus-host disease. , 2002, Blood.

[33]  Kenneth C. Anderson,et al.  Vascular Endothelial Growth Factor-induced Migration of Multiple Myeloma Cells Is Associated with β1 Integrin- and Phosphatidylinositol 3-Kinase-dependent PKCα Activation* , 2002, The Journal of Biological Chemistry.

[34]  S. Ansell,et al.  Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells , 2002, Leukemia.

[35]  Peter Lipsky,et al.  Cytokines and autoimmunity , 2002, Nature Reviews Immunology.

[36]  D. Ribatti,et al.  Bone Marrow Angiogenesis and Plasma Cell Angiogenic and Invasive Potential in Patients with Active Multiple Myeloma , 2002, Acta Haematologica.

[37]  K. Anderson,et al.  Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. , 2001, Blood.

[38]  K. Ohshima,et al.  Interleukin‐13 and interleukin‐13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis , 2001, Histopathology.

[39]  J. Bluestone,et al.  Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. , 2001, Annual review of immunology.

[40]  H. Augustin,et al.  Induction of inflammatory angiogenesis by monocyte chemoattractant protein‐1 , 1999, International journal of cancer.

[41]  S. Nishikawa,et al.  Vascular Endothelial Growth Factor Can Substitute for Macrophage Colony-Stimulating Factor in the Support of Osteoclastic Bone Resorption , 1999, The Journal of experimental medicine.

[42]  I. Riet.  Homing mechanisms of myeloma cells. , 1999 .

[43]  A. Sundan,et al.  The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies. , 1999, Leukemia & lymphoma.

[44]  G. Ahmann,et al.  Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. , 1999, Blood.

[45]  Y. Shoenfeld,et al.  Autoimmune diseases and autoimmunity post-bone marrow transplantation , 1998, Bone Marrow Transplantation.

[46]  S. Jagannath,et al.  CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.

[47]  A. Waage,et al.  Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. , 1998, Blood.

[48]  A. Lazzarin,et al.  Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. , 1998, Blood.

[49]  P. L. Bergsagel,et al.  Multiple myeloma: increasing evidence for a multistep transformation process. , 1998, Blood.

[50]  F. Bühling,et al.  Overproduction of IL-7, IL-10 and TGF-β1 in Multiple Myeloma , 1997 .

[51]  S. Woo,et al.  Graft-vs.-host disease. , 1997, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[52]  B. Klein,et al.  Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. , 1996, Blood.

[53]  W. Cruikshank,et al.  Interleukin 16 and its function as a CD4 ligand. , 1996, Immunology today.

[54]  P. Weller,et al.  CD4-mediated stimulation of human eosinophils: lymphocyte chemoattractant factor and other CD4-binding ligands elicit eosinophil migration , 1991, The Journal of experimental medicine.

[55]  H. Asaoku,et al.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas , 1988, Nature.

[56]  T. Bringman,et al.  Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. , 1987, The New England journal of medicine.

[57]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.